5 ms·

Intellectual curiosity

by oneoff786 4y ago

amluto 4y ago
It would be nice if the article said which experimental drug was used.
- Gordonjcp 4y ago
  It does. It's right there. Did you read the article?
  - amluto 4y ago
    Yes. > experimental medicine combined with Atezolizumab, an immunotherapy drug Atezolizumab is an approved anti-PD-L1 monoclonal antibody. What’s the experimental medicine?
    - Gordonjcp 4y ago
      Seems to have been ninja-edited. It was there earlier.
  - elromulous 4y ago
    It doesn't. Did _you_ read the article? > an experimental medicine combined with Atezolizumab, an immunotherapy drug. Atezolizumab is not the experimental drug, it's an already approved drug. The drug in question is the unnamed drug it was combined with.
    - Gordonjcp 4y ago
      Huh. It was there earlier. I can't remember what it said, a something-mab, so monoclonal antibody. I wonder why the BBC did a wee ninja-edit? Legal reasons?
- ok123456 4y ago
  A monocolony antibody.
- ma2t 4y ago
  The article doesn't give details, but one of the quoted authors has participated in trials testing anti-ICOS antibody alone or in combination with atezolizumab, with results presented at an ASCO meeting: https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.2624 https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.26... Describes one complete response in TNBC (and 4 partial responses in TNBC and other cancers). Couldn't find a related peer-reviewed journal article on very quick search.
  - adamredwoods 4y ago
    I have not heard of anti-ICOS (Inducible costimulatory receptor) before. Seems specific to TME. KY1044 with mouse models (different authors): https://aacrjournals.org/cancerimmunolres/article/8/12/1568/469583/An-Antibody-Targeting-ICOS-Increases-Intratumoral https://aacrjournals.org/cancerimmunolres/article/8/12/1568/... KY1044 I think is Kymab in Cambridge: https://www.kymab.com/pipeline/ky1044/ https://www.kymab.com/pipeline/ky1044/
    - ma2t 4y ago
      Yes, Sanofi licensed from Kymab. There are a few groups targeting ICOS/ICOSL to modulate immune response to tumor (either alone or in combo with PD-1, CTLA-4, etc approaches previously mentioned on HN). Here's one reasonably recent backgrounder on rationale: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003380/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003380/ Still not clear that KY1044 really is the "experimental drug" mentioned in the linked BBC article, since as others have noted the article is pretty thin on detail.

Intellectual curiosity

amluto 4y ago

It would be nice if the article said which experimental drug was used.

Gordonjcp 4y ago
It does. It's right there. Did you read the article?
- amluto 4y ago
  Yes. > experimental medicine combined with Atezolizumab, an immunotherapy drug Atezolizumab is an approved anti-PD-L1 monoclonal antibody. What’s the experimental medicine?
  - Gordonjcp 4y ago
    Seems to have been ninja-edited. It was there earlier.
- elromulous 4y ago
  It doesn't. Did _you_ read the article? > an experimental medicine combined with Atezolizumab, an immunotherapy drug. Atezolizumab is not the experimental drug, it's an already approved drug. The drug in question is the unnamed drug it was combined with.
  - Gordonjcp 4y ago
    Huh. It was there earlier. I can't remember what it said, a something-mab, so monoclonal antibody. I wonder why the BBC did a wee ninja-edit? Legal reasons?
ok123456 4y ago
A monocolony antibody.
ma2t 4y ago
The article doesn't give details, but one of the quoted authors has participated in trials testing anti-ICOS antibody alone or in combination with atezolizumab, with results presented at an ASCO meeting: https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.2624 https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.26... Describes one complete response in TNBC (and 4 partial responses in TNBC and other cancers). Couldn't find a related peer-reviewed journal article on very quick search.
- adamredwoods 4y ago
  I have not heard of anti-ICOS (Inducible costimulatory receptor) before. Seems specific to TME. KY1044 with mouse models (different authors): https://aacrjournals.org/cancerimmunolres/article/8/12/1568/469583/An-Antibody-Targeting-ICOS-Increases-Intratumoral https://aacrjournals.org/cancerimmunolres/article/8/12/1568/... KY1044 I think is Kymab in Cambridge: https://www.kymab.com/pipeline/ky1044/ https://www.kymab.com/pipeline/ky1044/
  - ma2t 4y ago
    Yes, Sanofi licensed from Kymab. There are a few groups targeting ICOS/ICOSL to modulate immune response to tumor (either alone or in combo with PD-1, CTLA-4, etc approaches previously mentioned on HN). Here's one reasonably recent backgrounder on rationale: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003380/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003380/ Still not clear that KY1044 really is the "experimental drug" mentioned in the linked BBC article, since as others have noted the article is pretty thin on detail.